Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients.

@article{Budde2010SotrastaurinAN,
  title={Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients.},
  author={Klemens Budde and Claudia Sommerer and Thomas Becker and Argiris Asderakis and Frank Pietruck and Josep Mar{\'i}a Grinyo and Paolo Rigotti and Jacques Dantal and Jennifer S. C. Ng and Markus Jan Barten and Markus Weber},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2010},
  volume={10 3},
  pages={571-81}
}
Sotrastaurin, a novel protein-kinase-C inhibitor, blocks early T-cell activation. In this 12-month, Phase II study, de novo renal-transplant patients were randomized to sotrastaurin (200 mg b.i.d.) + standard-exposure tacrolimus (SET) or reduced-exposure tacrolimus (RET) (SET: n = 76; RET: n = 66), or control (SET + mycophenolic acid [MPA, 720 mg b.i.d.]; n = 74). In both sotrastaurin groups, patients were converted from tacrolimus to MPA after Month 3, achieving calcineurin inhibitor-free… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…